NCT04197687 2023-12-18
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Phase 2 Unknown
Clinical Trials
11 trialsNCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05912062 2023-09-29
BiOnHER
Institut Català d'Oncologia
Unknown
NCT03412643 2023-03-06
FB-12
NSABP Foundation Inc
Phase 2 Unknown
NCT05738993 2023-02-22
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
Biocad
Phase 1 Unknown
NCT05656079 2022-12-19
easy laugh
Shanghai Pudong Hospital
Phase NA Unknown
NCT05483439 2022-08-05
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Phase 2 Unknown
NCT04683445 2020-12-24
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT03144947 2020-10-14
IMMUN-HER
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Unknown
NCT04246502 2020-02-05
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT02689921 2018-09-28
NEOADAPT
Midwestern Regional Medical Center
Phase 2 Unknown